Hypercholesterolemia effectively managed with homeopathic medicine Gautteria gaumeri (Yumel): results from a clinical study in academic clinical set up in north India


  • Aejaz Husain Lifeline Clinic, Udaipur, Rajasthan, India
  • Ashish Indani Tata Consultancy Services, Mumbai, Maharashtra, India http://orcid.org/0000-0002-3537-9044
  • Poonam Bhutada Krishnamugdha Institute of Advanced Learning and Research, Mumbai, Maharashtra, India




Cholesterol lowering, Dyslipidemia, Guatteria gaumeri, Hypercholesterolaemia, Hyperlipidemia, High cholesterol, Lipid profile, Lipid lowering, Statins, Yumel


Background: Hypercholesterolaemia increases the risk of atherosclerosis, subsequently IHD. Herbal-homeopathic medicines are unexplored as lipid-lowering agents. This study presents safety and efficacy outcomes of homeopathic Gautteria gaumeri Q, in treatment of hypercholesterolaemia.

Methods: This was a homoeopathic registry in real world population. A group of 29 subjects with mild to moderate hypercholesterolaemia with or without statin therapy were included in the study at a single centre in Udaipur, India. All subjects were given 10-15 drops of Gautteria gaumeri Q thrice in a day for 2 months and were followed fortnightly.

Results: The sample demographics were similar to typical Indian demographics (age 43±14 years, height 166.5cm, BMI 21kg/m2) having age 49±6 years, gender ratio 0.81 with 13 (45%) males and 16 (55%) females, height 157.07±26.18 cms and weight 71.5±11.78 Kg. The comorbidity included diabetes (44.83%), hypertension (68.97%), current smoking (44.83%) and CAD (31.03%). Thirteen (44.83%) subjects were taking statins for minimum 6 months. At baseline, mean TC, HDL, LDL, VLDL cholesterols and triglycerides were 223±25.8, 41.45±4.82, 150.9±25.97, 30.66±6.38 and 223±34.81 respectively. TC: HDL and LDL: HDL ratios were 5.44±0.82 and 3.69±0.77 respectively. At 2 months, TC reduced by 22.21 (9.96%), triglycerides, LDL and VLDL cholesterol demonstrated 39.55 (17.70%), 24.66 (16.34%) and 3.35 (10.91%) reduction respectively. HDL increased by 5.84 (14.09%). Proportion of population at risk defined as TC >200, LDL >120, VLDL >30, HDL <30 and triglycerides >200 was reduced by 17.24%, 31.04%, 13.79%, 100% and 31.03% respectively. (Baseline n=13). There were no ADRs in the study. Gauttaria gaumeri was proved to be efficacious in treatment of hypercholesterolaemia.

Conclusions: Guatteria gumeri was observed to be efficacious in controlling hypercholesterolaemia. There was no significant effect of statin therapy prior to starting Guatteria gaumeri Q. No safety issues were reported in the study.


Castelli WP. Epidemiology of coronary heart disease: the Framingham Study. Am J Med. 1984;76:4-12.

Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet. 1997;349:1269-76.

LaMorte WW, Matolo NM, Birkett DH, Williams LF. Pathogenesis of cholesterol gallstones. Surg Clin North Am. 1981;61(4):765-74.

Guyton C, Hall JE. Lipid metabolism. In: Guyton and Hall Textbook of Medical Physiology 12th ed. Elsevier Saunders; 2006:819-827.

Gotto A, Pownall H. Manual of lipid disorders: reducing the risk for coronary heart disease. 2nd ed. Baltimore, MD: Williams and Wilkins; 1999:19.

Gotto A, Pownall H. Manual of lipid disorders: reducing the risk for coronary heart disease. 2nd ed. Baltimore, MD: Williams and Wilkins; 1999:16.

Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. Washington, DC: AACC Press; 1997:14-15.

Gotto A, Pownall H. Manual of lipid disorders: reducing the risk for coronary heart disease. 2nd ed. Baltimore, MD: Williams and Wilkins; 1999:105-106.

Maher VM, Brown G. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol. 1995;6:229-35.

Scanu AM. Lipoprotein (a): a potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med. 1988:112:1045-7.

Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. Washington DC: AACC Press; 1997:12.

Gotto A, Assmann G, Carmena R. The International Lipid Handbook for Clinical Practice. 2nd ed. New York, NY: International Lipid Information Bureau; 2000:218.

National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD: National Heart, Lung and Blood Institute; 2001.

Liu ZL, Liu JP, Zhang AL, Wu Q, Ruan Y, Lewith G, et al. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev. 2011;(7):CD008305.

Yumel, Miguel A. Marmolejo the healing power of yumel or Guatteria gaumeri, 2016. Available at http://feelingkeep.com/article/the-healing-power-of-yumel-or-guatteria-gaumeri.

Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-33.

Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1084-91.

Stein ED, Sprecher KS, Allenby RL, Tosiello E, Whalen SR. A new potent synthetic hmg co-a reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardio Pharmacol Ther. 2016;2(1):7-16.

Eva Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Bjorkhem I, et al. Influence of pravastatin a specific inhibitor of HMG-CoA reductase on hepatic metabolism of cholesterol. New Eng J Med. 1990:224-228.

Olsson AG, Istad H, Luurila O, Ose L, Steen S, Tuomilehto J, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144(6):1044-51.

Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2016;35(9):1096-107.

Rodríguez-Páez L, Juárez-Sanchez M, Antúnez-Solís J, Baeza I, Wong C. Alpha-asarone inhibits HMG-CoA reductase, lowers serum LDL-cholesterol levels and reduces biliary CSI in hypercholesterolemic rats. Phytomed. 2003;10(5):397-404.






Original Research Articles